Moving on from Usama Malik's insider trading imbroglio, Fore resets at the top; Takeda spinout turns to Neurana CEO to lead the way
→ The ouster of former Immunomedics exec Usama Malik created a CEO opening at Fore Biotherapeutics, which is taking aim at BRAF mutations following a rebrand last year. Matthew Ros has now stepped up to the tee box as CEO and a member of the board after Malik was embroiled in an insider trading scandal during his time at Immunomedics that he chose to address in a rather cryptic LinkedIn post in December. A 17-year Bristol Myers Squibb vet, Ros left Sanofi Genzyme in 2016 to become COO of Epizyme, where he had since been chief strategy and business officer. Fore Bio, once known as diagnostics company NovellusDx and chaired by former Sanofi exec Dieter Weinand, is in a Phase I/IIa trial with its lead candidate FORE8394.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.